Drug intelligence / Profile preview

Aminopentamide

Development stage: Unknown
Lead developer: Bristol Laboratories
Modality: Small Molecules
Administration: Oral

Overview

Aminopentamide is a parasympatholytic agent. It has been shown to have broncholytic effects. It was administered to patients in the form of anti-diarrhoeal tablets. Aminopentamide is also used as an internal standard in gas-chromatographic methods for the quantification of other drugs like disopyramide.

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Aminopentamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aminopentamide.

Explore the full profile